Refractoriness and retreatment in the era of lenalidomide and mABs in the frontline myeloma setting

Bookmark and Share
Published: 18 Oct 2021
Views: 808
Rating:
Save
Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway

Dr Fredrik Schjesvold speaks to ecancer about the refractoriness and re-treatment go myeloma in the era of lenalidomide and mABs in the frontline setting.

Dr Schjesvold explains the background go his presentation at MyKe Myeloma 2021. He explains that many people have refractory disease in myeloma and there are three regimens approved for elderly and young people. He then mentions that patients can also be daratumuab refractory in the second line setting.

Dr Schjesvold concludes by discussing what treatment to give to people who are refractory and mentions several drugs that can be used for this purpose. 

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.